[{"id":"f2099dc8-cbfe-4cc7-a261-30a50590ba1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06547112","created_at":"2025-02-25T12:39:11.165Z","updated_at":"2025-02-25T12:39:11.165Z","phase":"Phase 1","brief_title":"A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization","source_id_and_acronym":"NCT06547112","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aphexda (motixafortide)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/31/2024","start_date":" 10/31/2024","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-02-24"},{"id":"bc60677c-4765-447b-a7fc-484791749d8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02907099","created_at":"2021-01-18T14:15:50.444Z","updated_at":"2025-02-25T14:01:05.330Z","phase":"Phase 2","brief_title":"Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT02907099","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Aphexda (motixafortide)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 10/06/2023","primary_completion_date":" 10/06/2023","study_txt":" Completion: 10/06/2023","study_completion_date":" 10/06/2023","last_update_posted":"2025-02-19"},{"id":"633b2bd1-281a-46a9-951a-65d15ed55de4","acronym":"NIR-II","url":"https://clinicaltrials.gov/study/NCT06713161","created_at":"2025-02-26T10:41:33.908Z","updated_at":"2025-02-26T10:41:33.908Z","phase":"","brief_title":"Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status","source_id_and_acronym":"NCT06713161 - NIR-II","lead_sponsor":"Yunnan Cancer Hospital","biomarkers":" CXCR4","pipe":"","alterations":" ","tags":["CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e balixafortide (POL 6326)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 08/25/2025","primary_completion_date":" 08/25/2025","study_txt":" Completion: 12/25/2025","study_completion_date":" 12/25/2025","last_update_posted":"2024-12-03"},{"id":"9006413d-c253-422b-9187-4e378c02068c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05561751","created_at":"2025-03-03T14:53:33.824Z","updated_at":"2025-03-03T14:53:33.824Z","phase":"Phase 2","brief_title":"Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant","source_id_and_acronym":"NCT05561751","lead_sponsor":"GPCR Therapeutics, Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e burixafor (GPC-100)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/13/2023","start_date":" 02/13/2023","primary_txt":" Primary completion: 03/29/2025","primary_completion_date":" 03/29/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-10-17"},{"id":"62911df7-cdd6-497a-b828-0b10ea364db9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06514508","created_at":"2025-02-27T07:51:39.520Z","updated_at":"2025-02-27T07:51:39.520Z","phase":"Phase 3","brief_title":"Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients","source_id_and_acronym":"NCT06514508","lead_sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aphexda (motixafortide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/30/2024","start_date":" 09/30/2024","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-07-23"},{"id":"e2c86e85-6b93-47fb-9960-a5caa4b6ea35","acronym":"MOZOBL06877","url":"https://clinicaltrials.gov/study/NCT03406091","created_at":"2021-01-18T16:48:18.086Z","updated_at":"2024-07-02T16:35:18.698Z","phase":"","brief_title":"Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients","source_id_and_acronym":"NCT03406091 - MOZOBL06877","lead_sponsor":"Fondazione EMN Italy Onlus","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 300","initiation":"Initiation: 11/26/2015","start_date":" 11/26/2015","primary_txt":" Primary completion: 01/19/2021","primary_completion_date":" 01/19/2021","study_txt":" Completion: 01/17/2024","study_completion_date":" 01/17/2024","last_update_posted":"2024-02-20"},{"id":"b2e75f74-db69-4c42-84da-91c55330e291","acronym":"GENESIS","url":"https://clinicaltrials.gov/study/NCT03246529","created_at":"2021-01-18T16:02:27.221Z","updated_at":"2024-07-02T16:35:20.176Z","phase":"Phase 3","brief_title":"A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous TransplantatIon in Subjects With MM","source_id_and_acronym":"NCT03246529 - GENESIS","lead_sponsor":"BioLineRx, Ltd.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aphexda (motixafortide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 12/22/2020","primary_completion_date":" 12/22/2020","study_txt":" Completion: 09/30/2029","study_completion_date":" 09/30/2029","last_update_posted":"2024-02-08"},{"id":"dfd7ee50-87ba-4fb1-b93e-f7b46ce89192","acronym":"","url":"https://clinicaltrials.gov/study/NCT02639559","created_at":"2021-01-18T12:50:23.655Z","updated_at":"2024-07-02T16:35:30.301Z","phase":"Phase 2","brief_title":"Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies","source_id_and_acronym":"NCT02639559","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aphexda (motixafortide)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 03/31/2016","start_date":" 03/31/2016","primary_txt":" Primary completion: 04/12/2018","primary_completion_date":" 04/12/2018","study_txt":" Completion: 04/07/2023","study_completion_date":" 04/07/2023","last_update_posted":"2023-11-06"},{"id":"2d84d56d-dda0-4e45-bc47-da746b822f0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01696461","created_at":"2021-01-18T07:22:14.622Z","updated_at":"2024-07-02T16:35:36.969Z","phase":"Phase 2","brief_title":"A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor","source_id_and_acronym":"NCT01696461","lead_sponsor":"Center for International Blood and Marrow Transplant Research","biomarkers":" CD33 • CD34","pipe":"","alterations":" ","tags":["CD33 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 127","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 08/01/2016","primary_completion_date":" 08/01/2016","study_txt":" Completion: 08/01/2016","study_completion_date":" 08/01/2016","last_update_posted":"2023-09-14"},{"id":"f6a843ff-b9a4-47ba-9949-917077f9fea2","acronym":"POLTER","url":"https://clinicaltrials.gov/study/NCT04826016","created_at":"2021-04-01T16:52:30.884Z","updated_at":"2024-07-02T16:35:53.007Z","phase":"Phase 1/2","brief_title":"POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer","source_id_and_acronym":"NCT04826016 - POLTER","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • Halaven (eribulin mesylate) • balixafortide (POL 6326)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/16/2022","start_date":" 03/16/2022","primary_txt":" Primary completion: 03/16/2022","primary_completion_date":" 03/16/2022","study_txt":" Completion: 03/16/2022","study_completion_date":" 03/16/2022","last_update_posted":"2023-03-20"},{"id":"c39bcb1d-4ab0-4b6b-b2bd-56001aac7f38","acronym":"","url":"https://clinicaltrials.gov/study/NCT05510544","created_at":"2022-08-22T13:04:22.282Z","updated_at":"2024-07-02T16:35:53.476Z","phase":"Phase 4","brief_title":"Plerixafor for Poorly Mobilized Lymphoma","source_id_and_acronym":"NCT05510544","lead_sponsor":"Peking University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plerixafor"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 12/19/2022","start_date":" 12/19/2022","primary_txt":" Primary completion: 12/20/2023","primary_completion_date":" 12/20/2023","study_txt":" Completion: 01/31/2024","study_completion_date":" 01/31/2024","last_update_posted":"2023-03-13"},{"id":"5e54474b-d2cf-495a-a3c2-dafc873e6e05","acronym":"","url":"https://clinicaltrials.gov/study/NCT05087212","created_at":"2021-10-21T12:53:04.089Z","updated_at":"2024-07-02T16:35:56.705Z","phase":"Phase 4","brief_title":"Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients","source_id_and_acronym":"NCT05087212","lead_sponsor":"Sanofi","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 10/22/2021","start_date":" 10/22/2021","primary_txt":" Primary completion: 12/06/2022","primary_completion_date":" 12/06/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2023-01-31"},{"id":"100d53c1-a871-4c02-b038-7972188d3735","acronym":"","url":"https://clinicaltrials.gov/study/NCT03317899","created_at":"2021-01-18T16:23:07.420Z","updated_at":"2024-07-02T16:36:00.230Z","phase":"Phase 2","brief_title":"Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03317899","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neupogen (filgrastim) • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 10/12/2017","start_date":" 10/12/2017","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 11/16/2022","study_completion_date":" 11/16/2022","last_update_posted":"2022-11-17"},{"id":"ea8cd680-2cf6-43af-ad88-79a19110de77","acronym":"IRB-57056","url":"https://clinicaltrials.gov/study/NCT04552743","created_at":"2021-01-18T21:46:04.906Z","updated_at":"2024-07-02T16:36:04.116Z","phase":"Phase 2","brief_title":"MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma","source_id_and_acronym":"NCT04552743 - IRB-57056","lead_sponsor":"Surbhi Sidana, MD","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGTA-145 • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 10/05/2020","start_date":" 10/05/2020","primary_txt":" Primary completion: 07/22/2021","primary_completion_date":" 07/22/2021","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2022-09-12"},{"id":"5c09082e-b1b0-4cba-bff1-cce800759223","acronym":"","url":"https://clinicaltrials.gov/study/NCT05103917","created_at":"2021-11-02T17:57:12.570Z","updated_at":"2024-07-02T16:36:21.656Z","phase":"Phase 1/2","brief_title":"A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC","source_id_and_acronym":"NCT05103917","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Xolremdi (mavorixafor)"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 24","initiation":"Initiation: 07/21/2021","start_date":" 07/21/2021","primary_txt":" Primary completion: 11/24/2022","primary_completion_date":" 11/24/2022","study_txt":" Completion: 05/21/2023","study_completion_date":" 05/21/2023","last_update_posted":"2021-11-02"},{"id":"c5cbefb4-2b0f-4701-a9a1-8be7116f6272","acronym":"","url":"https://clinicaltrials.gov/study/NCT01018979","created_at":"2021-01-18T03:59:46.250Z","updated_at":"2024-07-02T16:36:30.431Z","phase":"Phase 2","brief_title":"Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients","source_id_and_acronym":"NCT01018979","lead_sponsor":"GPCR Therapeutics, Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e burixafor (GPC-100)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 02/01/2010","start_date":" 02/01/2010","primary_txt":" Primary completion: 10/01/2011","primary_completion_date":" 10/01/2011","study_txt":" Completion: 10/01/2011","study_completion_date":" 10/01/2011","last_update_posted":"2021-05-11"},{"id":"7de24069-d0e2-4dc0-9608-66a93029fa5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02104427","created_at":"2021-01-18T09:43:26.119Z","updated_at":"2024-07-02T16:36:31.554Z","phase":"Phase 2","brief_title":"PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients","source_id_and_acronym":"NCT02104427","lead_sponsor":"GPCR Therapeutics, Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e burixafor (GPC-100)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 11/01/2015","primary_completion_date":" 11/01/2015","study_txt":" Completion: 11/01/2015","study_completion_date":" 11/01/2015","last_update_posted":"2021-04-19"},{"id":"98650662-105e-4826-8b8e-4e5e0cb66828","acronym":"","url":"https://clinicaltrials.gov/study/NCT01458288","created_at":"2021-01-18T06:03:35.087Z","updated_at":"2024-07-02T16:36:31.894Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease","source_id_and_acronym":"NCT01458288","lead_sponsor":"GPCR Therapeutics, Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e burixafor (GPC-100)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 07/01/2013","study_completion_date":" 07/01/2013","last_update_posted":"2021-04-19"},{"id":"78a08048-158a-4be0-94e8-5e7757b32c7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01753453","created_at":"2021-01-18T07:41:53.252Z","updated_at":"2024-07-02T16:36:34.223Z","phase":"Phase 2","brief_title":"An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells","source_id_and_acronym":"NCT01753453","lead_sponsor":"Sanofi","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 06/01/2013","start_date":" 06/01/2013","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 09/01/2016","study_completion_date":" 09/01/2016","last_update_posted":"2021-02-23"},{"id":"ebdeb635-d206-4c76-a258-53dd95830adc","acronym":"IFM-2015-03","url":"https://clinicaltrials.gov/study/NCT02439476","created_at":"2021-01-18T11:41:09.380Z","updated_at":"2024-07-02T16:36:35.885Z","phase":"","brief_title":"Non-interventional Study on Salvage Auto in Relapsed Myeloma","source_id_and_acronym":"NCT02439476 - IFM-2015-03","lead_sponsor":"Association for Training, Education, and Research in Hematology, Immunology, and Transplantation","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 08/08/2016","start_date":" 08/08/2016","primary_txt":" Primary completion: 08/08/2020","primary_completion_date":" 08/08/2020","study_txt":" Completion: 08/08/2020","study_completion_date":" 08/08/2020","last_update_posted":"2021-01-20"},{"id":"039b01a5-289c-432a-8db6-4ba36c0d53c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02343666","created_at":"2021-01-18T11:08:26.454Z","updated_at":"2024-07-02T16:37:05.148Z","phase":"Phase 1","brief_title":"HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection","source_id_and_acronym":"NCT02343666","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD34 • CD4","pipe":"","alterations":" ","tags":["CD34 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carmustine • Neupogen (filgrastim) • plerixafor"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/15/2016","start_date":" 08/15/2016","primary_txt":" Primary completion: 08/01/2020","primary_completion_date":" 08/01/2020","study_txt":"","study_completion_date":"","last_update_posted":"2018-11-20"},{"id":"784befad-6ca4-4afd-82e0-e21a4760b690","acronym":"","url":"https://clinicaltrials.gov/study/NCT01837095","created_at":"2021-01-17T17:26:17.947Z","updated_at":"2024-07-02T16:37:06.883Z","phase":"Phase 1","brief_title":"Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT01837095","lead_sponsor":"Polyphor Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • balixafortide (POL 6326)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 06/01/2013","start_date":" 06/01/2013","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 08/01/2018","study_completion_date":" 08/01/2018","last_update_posted":"2018-09-14"},{"id":"5196c7bf-5bf9-4cf9-8711-f852ccafb593","acronym":"","url":"https://clinicaltrials.gov/study/NCT01319864","created_at":"2021-01-18T05:22:22.912Z","updated_at":"2024-07-02T16:37:07.140Z","phase":"Phase 1","brief_title":"POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients","source_id_and_acronym":"NCT01319864","lead_sponsor":"Seattle Children's Hospital","biomarkers":" CXCR4","pipe":" | ","alterations":" CXCR4 expression","tags":["CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCR4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 06/28/2013","primary_completion_date":" 06/28/2013","study_txt":" Completion: 06/28/2016","study_completion_date":" 06/28/2016","last_update_posted":"2018-09-07"},{"id":"ab864958-399d-451e-b668-5eba2ff86a0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01352650","created_at":"2021-01-18T05:31:47.169Z","updated_at":"2024-07-02T16:37:09.315Z","phase":"Phase 1","brief_title":"Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT01352650","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" RUNX1 • PML","pipe":"","alterations":" ","tags":["RUNX1 • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 71","initiation":"Initiation: 06/17/2011","start_date":" 06/17/2011","primary_txt":" Primary completion: 12/27/2016","primary_completion_date":" 12/27/2016","study_txt":" Completion: 12/27/2016","study_completion_date":" 12/27/2016","last_update_posted":"2018-07-02"}]